Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression.

@article{Sasaki2011Bcl2IA,
  title={Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression.},
  author={Nana Sasaki and Junya Kuroda and Hisao Nagoshi and Mio Yamamoto and Satoru Kobayashi and Yasuhiko Tsutsumi and Tsutomu Kobayashi and Yuji Shimura and Yosuke Matsumoto and Tomohiko Taki and Kazuhiro Nishida and Shigeo Horiike and Yukihiro Akao and Masafumi Taniwaki},
  journal={Experimental hematology},
  year={2011},
  volume={39 8},
  pages={817-28.e1}
}
OBJECTIVE The prognosis for diffuse large B-cell lymphomas with concomitant overexpression of c-Myc and Bcl-2 remains dismal; there is an urgent need to clarify the significance of these two oncogenes as therapeutic targets for a more effective treatment strategy. MATERIALS AND METHODS We established two novel cell lines, KPUM-MS3 and KPUM-UH1, from two chemoresistant patients with diffuse large B-cell lymphomas with concomitant overexpression of c-Myc and Bcl-2, and investigated the… CONTINUE READING
19 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

Similar Papers

Loading similar papers…